Evolus, Inc. Files Q1 2025 10-Q Report
Ticker: EOLS · Form: 10-Q · Filed: May 7, 2025 · CIK: 1570562
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Evolus Q1 2025 10-Q filed. Financials out.
AI Summary
Evolus, Inc. filed its 10-Q for the period ending March 31, 2025. The company, operating in pharmaceutical preparations, reported financial data for the first quarter of 2025 and the comparable period in 2024. Key financial metrics and product-related information were disclosed.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Evolus, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025)
- 2024-01-01 to 2024-03-31 — Prior Year Period (Comparable period in 2024)
Key Players & Entities
- Evolus, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- Newport Beach, CA (location) — Company headquarters
FAQ
What is the primary business of Evolus, Inc. according to the filing?
Evolus, Inc. is classified under Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Evolus, Inc.?
The fiscal year end for Evolus, Inc. is December 31 (1231).
When was this 10-Q form filed?
This 10-Q form was filed on May 7, 2025 (20250507).
What is the SEC file number for Evolus, Inc.?
The SEC file number for Evolus, Inc. is 001-38381.
What are the business and mailing addresses for Evolus, Inc.?
The business and mailing addresses for Evolus, Inc. are located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Evolus, Inc. (EOLS).